Patients' and physicians' preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experiment by Morillas, Carlos et al.
© 2015 Morillas et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)  
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on 
how to request permission may be found at: http://www.dovepress.com/permissions.php
Patient Preference and Adherence 2015:9 1443–1458
Patient Preference and Adherence Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
1443
O r i g i n A l  r e s e A r c h
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/PPA.S88022
Patients’ and physicians’ preferences for type 2  
diabetes mellitus treatments in spain and Portugal: 
a discrete choice experiment
carlos Morillas1
rosa Feliciano2
Pablo Fernández catalina3
carla Ponte4
Marta Botella5
João rodrigues6
enric esmatjes7
Javier lafita8
luis lizán9
ignacio llorente10
cristóbal Morales11
Jorge navarro-Pérez12
Domingo Orozco-Beltran13
silvia Paz9
Antonio ramirez de Arellano14
cristina cardoso15
Maribel Tribaldos causadias9
1hospital Universitario Dr Peset, 
Valencia, spain; 2UsF são Domingos, 
santarém, Portugal; 3hospital Montecelo 
de Pontevedra, galicia, spain; 4UsF Porta 
do sol, Matosinhos, Portugal; 5hospital 
Universitario Principe de Asturias, Madrid, 
spain; 6UsF serra da lousã, lousã, Portugal; 
7hospital clinic, Barcelona, spain; 8hospital 
de navarra, navarra, spain; 9Outcomes’10, 
Universidad Jaume i, castellón, spain; 
10hospital Universitario nuestra señora 
de la candelaria, canarias, spain; 11hospital 
Universitario Virgen de la Macarena, sevilla, 
spain; 12incliVA, ciBeresP, Universidad de 
Valencia, Valencia, spain; 13sociedad española 
de Medicina Familiar y comunitaria, 
Valencia, spain; 14novo nordisk eU-heOr 
europe, Madrid, spain; 15novo nordisk, 
lisbon, Portugal
Objective: To assess Spanish and Portuguese patients’ and physicians’ preferences regarding 
type 2 diabetes mellitus (T2DM) treatments and the monthly willingness to pay (WTP) to gain 
benefits or avoid side effects.
Methods: An observational, multicenter, exploratory study focused on routine clinical practice 
in Spain and Portugal. Physicians were recruited from multiple hospitals and outpatient clinics, 
while patients were recruited from eleven centers operating in the public health care system 
in different autonomous communities in Spain and Portugal. Preferences were measured via a 
discrete choice experiment by rating multiple T2DM medication attributes. Data were analyzed 
using the conditional logit model.
Results: Three-hundred and thirty (n=330) patients (49.7% female; mean age 62.4 [SD: 10.3] 
years, mean T2DM duration 13.9 [8.2] years, mean body mass index 32.5 [6.8] kg/m2, 41.8% 
received oral + injected medication, 40.3% received oral, and 17.6% injected treatments) and 
221 physicians from Spain and Portugal (62% female; mean age 41.9 [SD: 10.5] years, 33.5% 
endocrinologists, 66.5% primary-care doctors) participated. Patients valued avoiding a gain 
in bodyweight of 3 kg/6 months (WTP: €68.14 [95% confidence interval: 54.55–85.08]) the 
most, followed by avoiding one hypoglycemic event/month (WTP: €54.80 [23.29–82.26]). 
Physicians valued avoiding one hypoglycemia/week (WTP: €287.18 [95% confidence interval: 
160.31–1,387.21]) the most, followed by avoiding a 3 kg/6 months gain in bodyweight and 
decreasing cardiovascular risk (WTP: €166.87 [88.63–843.09] and €154.30 [98.13–434.19], 
respectively). Physicians and patients were willing to pay €125.92 (73.30–622.75) and €24.28 
(18.41–30.31), respectively, to avoid a 1% increase in glycated hemoglobin, and €143.30 
(73.39–543.62) and €42.74 (23.89–61.77) to avoid nausea.
Conclusion: Both patients and physicians in Spain and Portugal are willing to pay for the 
health benefits associated with improved diabetes treatment, the most important being to avoid 
hypoglycemia and gaining weight. Decreased cardiovascular risk and weight reduction became 
the third most valued attributes for physicians and patients, respectively.
Keywords: diabetes, discrete choice model, preferences, willingness to pay, hypoglycemia, 
weight, cardiovascular risk, HbA
1c
Introduction
Diabetes mellitus is a complex chronic illness requiring continuous medical care 
with multifactorial risk reduction strategies beyond glycemic control.1 It is one of the 
most common metabolic disorders in the world and its prevalence in adults has been 
increasing for decades. The prevalence of type 2 diabetes mellitus (T2DM) in Spain 
has been projected between 12.5%2 and 13.8%,3 while in Portugal the prevalence has 
been estimated to be 7.2%.4 According to the Global estimates of diabetes prevalence 
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for 2013, these numbers are expected to rise to 14.4% and 
15.8%, respectively, by 2035.5
The increasing prevalence of T2DM has stimulated the 
development of many new approaches to treat hypergly-
cemia safely. The treatment aims in T2DM are to reduce 
and maintain glucose concentrations as close to normal for 
as long as possible and thereby prevent the appearance of 
complications.6 However, despite the benefits of therapy, 
studies have indicated that recommended glycemic goals are 
achieved by less than 50% of patients, which may be associ-
ated with decreased adherence to medications.7
Medication adherence in T2DM is determined by differ-
ent factors including patient-centered concerns and beliefs 
about diabetes as a disease. Moreover, insufficient under-
standing of the benefits of medication and its side effects, 
difficulty following lifestyle recommendations as part of the 
health care plan, medication and health care cost, confusion 
about how to take medications, and psychological issues 
associated with chronic disease management can all have 
an influence on medication adherence.8
Including patients’ preferences into routine clinical prac-
tice has been related with an increment in medication adher-
ence, improvements in treatment outcomes, and reduced 
health care cost.9 Several publications that study patients’ 
preferences for diabetes medications have been identified 
in the literature. Conversely, information about physicians’ 
preferences regarding T2DM has only been identified in two 
publications,10,11 thus showing that physicians’ preferences 
can be considered as rational, reasonable, and of great value.12 
However, physician and patients disagree about how much 
risk is tolerable to achieve improvements in efficacy, given 
that patients are less tolerant in trading risk than physicians 
are, since the latter also placed great value on effectiveness/
efficacy. On the other hand, patients placed greater value on 
the importance of health-related quality of life (HRQoL) and 
social attributes than physicians’ believed.13
Although it might seams that this topic has been widely 
studied, it has not been addressed in patients and physicians 
in Spain and Portugal, and considering that a patient-centered 
communication style that incorporates patient preferences 
into physicians’ judgments is recognized as a strategy for 
improving diabetes care,14 the information provided by the 
current study can help overcome the challenge of understand-
ing patients’ behavior and vision of their own health, which 
can lead to a better diabetes control.
Discrete choice experiments (DCE) allow the analysis 
of preferences for complex multiattribute goods, such as 
medications.15 This technique is used in market research 
to assess how consumers value the characteristics that 
comprise a specific product, described in terms of underlying 
attributes.16 DCE are distinct from other conjoint methods 
because preferences are elicited by asking the respondent 
to choose one alternative from those presented, simulating 
real market situations.17 When out-of-the-pocket cost is 
included as an attribute in the DCE, the results can be used 
to calculate the willingness to pay (WTP) for the attributes 
being measured.18
This study aims to assess the preferences of Spanish and 
Portuguese patients with T2DM and their physicians with 
regard to diabetes treatments, including their side effects and 
methods of administration. Additional objectives are to deter-
mine the T2DM patients’ and physicians’ WTP to achieve 
certain therapeutic benefits and avoid side effects, as well 
as their WTP for alternative ways of treatment administra-
tion and changes in the frequency of self-monitoring blood 
glucose levels. Achieving these aims will in turn make it 
possible to identify the factors that may explain the patients’ 
and physicians’ preferences and to recognize potential dif-
ferences between T2DM patients and physicians.
Methods
Design
This is an observational, descriptive, multicenter, exploratory 
study in the context of routine clinical practice in Spain 
and Portugal, not linked to any specific antidiabetic drug 
or treatment.
Discrete choice experiment
This technique is an attribute-based measure of benefit, 
based on the assumption that health care interventions can be 
described by their attributes and that an individual’s evalua-
tion depends upon the levels of these attributes. Respondents 
are asked to choose between two alternatives. Resulting 
choices reveal an underlying utility function.19 Examples 
of alternatives presented to responders are described in 
Figures 1 and 2.
Medication attributes and levels selection
In accordance with the International Society for Pharmaco-
economics and Outcomes Research (ISPOR) good practices 
for conjoint analysis in health, the methodology for survey 
instrument development included: 1) Identification of 
medication attributes and levels, 2) Medication attributes 
and levels selection, 3) Experimental design, and 4) Con-
struction of task.20
For the identification of attributes and levels, a compre-
hensive literature review with the objective of identifying, 
selecting, and summarizing published studies that assessed 
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the preferences of T2DM patients for the attributes of antidi-
abetic treatments and/or their WTP for gaining health benefits 
or avoiding side effects was performed. Key words in English 
and Spanish joined by Booleans operators “or” and “and” 
(“diabetes mellitus”, “type 2 diabetes mellitus”, “treatment”, 
“medication”, “conjoint”, “conjoint analysis”, “conjoint 
measurement”, “conjoint studies”, “discrete choice experi-
ments”, “DCE”, “discrete choice modeling”, and “preference 
studies”) were used. The search was carried out in a pool of 
free publicly-accessible databases that are recommended 
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Figure 1 example of choice question convenience attributes.
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Figure 2 example of choice question clinical attributes.
Abbreviation: hbA1c, glycated hemoglobin.
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by the Cochrane Handbook for Systematic Reviews of 
Interventions21 and in the main national (Spanish) databases 
(MedLine/PubMed, Cochrane Library, ISI WOK, SCOPUS, 
and Medicina en Español-MEDES). Articles published until 
October 1, 2013 were selected.
Seven publications studying the preferences of T2DM 
patients for the attributes of antidiabetic treatments and/
or their WTP for gaining health benefits or avoiding side 
effects were retrieved.10,22–27 Although the questionnaire 
used for this study was based on surveys utilized previ-
ous studies, due to cultural differences between studied 
populations and Spanish and Portuguese people, it was 
deemed important to confirm that the attributes and levels 
identified in the literature were also important for Spain 
and Portugal.28,29
For that purpose, an online consult with a group of six 
diabetes’ experts (three endocrinologists from Spain and 
Portugal, respectively) with vast experience in the manage-
ment of T2DM and another consult with nine patients helped 
define, from the attributes and levels of antidiabetics that 
were identified, the ones that represented the antidiabetic 
medication characteristics that were more significant for 
these patients and clinical practice.
The result of such consults produced eight attributes 
and 28 levels. Given the amount of attributes levels, 
a decision was made to divide the attributes into two 
groups: convenience attributes (mode of administration 
and blood glucose monitoring) and clinical attributes 
(number of hypoglycemic events, glycated hemoglobin – 
HbA
1c
, bodyweight change in 6 months, nausea, and 
cardiovascular risk) performing two separate DCE. Fur-
thermore, additional cost per month was included as an 
attribute in the choice question so as to enable calculation 
of the WTP (Table 1).
experimental design and survey instrument
Following the recommendations of the ISPOR task force 
report,30 the R statistical software package31 was used to 
generate the DCE design that complied with the desirable 
properties of orthogonality and balance. The orthogonal 
design ensured that the resulting parameter estimates were 
uncorrelated and could be determined independently of the 
other attributes, while a balanced design ensured that the 
attribute levels occurred with equal frequency within each 
attribute, yielding equally robust results for all levels.23 Two 
fractional factorial analysis (orthogonal matrix), one for 
each group of attributes, produced two blocks of 16 sets of 
choices (scenarios) each containing multiple choices linked 
together in each question. Resulting scenarios were checked 
for dominated alternatives. Dominated alternatives were 
treated according to ISPOR guidelines.30
Considering the length of the sociodemographic and clini-
cal variables questions included in the survey and the fact 
that respondents may present fatigue after 17 choice sets,32 
following the standard practice, the sets of choices were 
distributed among four versions of questionnaires of eight 
multiple choice questions apiece (four convenience attribute 
scenarios and four clinical attribute scenarios). Physicians 
and patients were randomly assigned to one version of the 
survey. Examples of choice sets for each group of attributes 
are presented in Figures 1 and 2.
The final survey instruments for physicians included 
sociodemographic variables and the DCE for convenience 
and clinical attributes, while the surveys used for patients 
included three sections: clinical variables, including current 
diabetes treatment, to be completed by the physician, and 
sociodemographic and clinical variables to be completed 
by the patients, and the DCE for convenience and clinical 
Table 1 Attributes and levels for the choice questions
Attributes Levels
Mode of administration injections twice a day in relation to meals
injection once a day in relation to meals
injection once a day irrespective of meals
Oral antidiabetics (OAD) up to three times 
a day with meals
Blood glucose monitoring Three times a day
Once a day
Three times per week
no need for testing
number of hypoglycemic  
events
none
Once a week
Once a month
Once a year
hbA1c 6%
6%–7%
7%–8%
8%
Weight change in 6 months gain 3 kg
remains the same weight
loses 3 kg
loses 6 kg
nausea Mild nausea for up to 3 months
none
cardiovascular risk Decreases
remains the same
Additional payment  
per month
€100
€50
€20
€0
Abbreviation: hbA1c, glycated hemoglobin.
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attributes. The questionnaire did not contain any information 
regarding any specific diabetes medication.
study sample and data collection 
procedures
A sample size of 195 physicians and 267 patients was 
estimated using the maximum variability criterion, with a 
confidence level of 95% and assuming that the variability 
in response preferences would be higher within the patients 
group. A precision of 7% for the group of physicians and of 
6% for the group of patients was considered in order to obtain 
a larger sample of patients in comparison with the physicians. 
Other parameters used were the size of the Spanish and 
Portuguese adult population (between 20 and 79 years)33,34 
and the T2DM prevalence of 12.5%2 and 7.2%,4 respectively, 
for patients and the number of primary-care physicians and 
family medicine doctors operating in the public health care 
system in Spain35 and Portugal,36 respectively. Although new 
practical guides for sample size requirements for DCE have 
recently been published,37 this publication also states that 
for DCE designs, sample sizes over 100 are able to provide 
a basis for modeling preference data.
Sample size was distributed proportionally throughout 
Spain and Portugal. Physicians were recruited from diverse 
hospitals and outpatient clinics located throughout both ter-
ritories, while patients were recruited from eleven centers 
(hospitals and outpatient clinics) operating in the national 
health care system in different autonomous communities in 
Spain and Portugal.
Physicians were selected if they were primary-care 
doctors, family medicine doctors, or endocrinologists with 
at least 3 years’ experience in managing T2DM patients and 
were working in the national health care system in either of 
the countries. Inclusion criteria for patients comprised: being 
over 18 years old, diagnosed with T2DM for at least 5 years, 
and receiving treatment during the year prior to inclusion.
Physicians were invited to participate by answering an 
online survey. Physicians were asked which of the hypotheti-
cal treatments they would like to prescribe to their patients 
considering the attributes levels presented in each of the 
choice task. In other words, physicians were asked to choose 
which treatment they were willing to prescribe for a given 
cost if it would guarantee the associated benefits.
Patients were recruited from medical consults. During 
face-to-face interviews, patients who agreed to participate 
and signed the informed consent, were asked to complete a 
printed study survey. To make sure participants understood 
the DCE exercise, an internal consistency check was included 
at the beginning of the DCE. This included a dominance test, 
where one option was clearly superior to the other. Respon-
dents that failed the test were excluded from the analysis.38
statistical analyses
Once the collection of data was completed, a database 
containing the DCE results for each group of participants 
(physicians and patients) was created. The database was 
validated and checked for consistency and errors before 
the descriptive analyses were performed. These descriptive 
analyses included relative and absolute frequency calcula-
tions for qualitative variables, and central tendency and 
dispersion measures for quantitative ones, for each group 
of participants.
For the analysis of the DCE data, the conditional logit 
model was used, which is available through the mlogit 
statistical package of the R statistical software.39 This model 
is recommended when the attributes that are included in 
the hypothetical treatment are the only variables that are to 
be assessed. The conditional logit model is a mathematical 
regression model designed to estimate the part-worth (β) of 
the attribute level (characteristic) that contributes to the util-
ity of each hypothetical treatment presented in the discrete 
choice. The utility corresponds to the value that individuals 
assign to a product through the combination of its attributes, 
so that its value is the maximum for the choice made in a 
set of options. From these utility values, the probability of 
each treatment being selected is calculated. The higher the 
utility value, the higher the probability of a treatment being 
selected, and fulfilling the rule that the sum of all probabilities 
adds up to one.40
For the analysis of the convenience and clinical attributes, 
two models were constructed, one for each group of attri-
butes. The attributes characterizing the treatments were col-
lected and coded as qualitative variables, named as variables 
with different dummy categories, defined by the levels that 
were included. Given that individuals typically show a rela-
tive disregard for distant gains and losses in comparison with 
more immediate ones,41,42 and that in routine clinical practice 
it is recommended to set short-term weight goals in 6-month 
frames,43 the statistical analysis of the hypoglycemic events 
and weight attributes was performed using the attributes just 
as they were asked (categorical variables), thus avoiding bias. 
However, a linear transformation of certain attributes was 
considered (transformation of some levels into values). These 
changes were tested using likelihood tests. The transformed 
variables were blood glucose monitoring (per month), HbA
1c
, 
and additional payment per month.
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As the importance of different attributes cannot be 
compared directly using the parameter estimates due 
to the likelihood of confounding with the underlying 
utility scales, the relative impact of attributes is usually 
examined by converting estimates into a common scale, 
in this case the marginal rates of substitution in the form 
of WTP.44
The WTP for the attribute levels was obtained from the 
quotient between the utility value of each attribute and the 
utility value calculated for the payment.20 Although the WTP 
calculations are the same for qualitative and quantitative 
variables, certain nuances must be considered:
•	 Quantitative variables: when an attribute is expressed as 
a quantitative variable (ie, HbA
1c
), the WTP is obtained 
directly from the utility values of the given attribute and 
the payment. It is interpreted as the cost that a participant 
is willing to pay to increase the attribute by one unit 
(ie, WTP to increase HbA
1c
 by 1%).
•	 Qualitative variables: when an attribute is expressed as 
a qualitative variable (ie, mode of administration), WTP 
is obtained from the quotient between the difference in 
utility values among the categories to be exchanged and 
the payment. It is interpreted as the cost that a participant 
is willing to pay in order to change the attribute being 
assessed (ie, WTP for oral antidiabetics instead of injec-
tions in relation to meals).
Since WTP was calculated as a ratio between two 
variables, confidence intervals (CIs) could not be derived 
directly from the parameters of the conditional logit estima-
tion, and therefore the bootstrap technique was utilized. The 
purpose of this methodology is to simulate a large number 
of samples with replacements (10,000 simulations) of the 
same size as the original sample used in the study. In these 
samples, the Krinsky Robb method for obtaining the CIs 
was used.45
To identify conditioning factors that might explain either 
physicians’ or patients’ preferences, a multinomial logit 
model was used, where the preferences will be the dependent 
variables and the sociodemographic and clinical variables 
the explanatory ones.39 For the comparison of results among 
patients and physicians, the Z-test was utilized. This test is 
used for the comparison of regression coefficients when they 
have been estimated by maximum likelihood, as in the case 
of a conditional logit model.46–48
ethical considerations
This study followed the principles of the Declaration of 
Helsinki. It was developed to ensure that Good Clini-
cal Practices were observed and in keeping with The 
Tripartite Harmonized ICH Guideline49 principles. The 
study protocol was submitted to the Agencia Española 
del Medicamento y Productos Sanitarios and Comissão 
Nacional de Protecção de Dados for its classification and 
to all participant centers’ Clinical Research Ethic Com-
mittees for approval. Data were treated confidentially 
and dissociated in accordance with the Spanish (15/1999 
Personal Data Protection Law) and Portuguese regulation 
(Lei no 67/98).
Results
Patients’ results
Three-hundred and fifty-five patients were recruited. From 
those 25 were excluded due to failure in the DCE dominance 
test. Three-hundred and thirty patients participated in the 
study; 84% of them were Spaniards and were distributed 
similarly by sex. Patients had a mean age of 62.4 (SD: 10.3) 
years. Mean body mass index (32.5±6.8) showed an obese 
population in which more than half (53%) presented T2DM 
complications. All sociodemographic and clinical variables 
are presented in Table 2.
The analysis showed that, with the exception of one 
hypoglycemic event per month, all attributes were significant 
predictors of choice (P0.05). Avoiding gaining 3 kg/6 
months was the most valued attribute followed by avoiding 
one hypoglycemia event per month (Table 3). The WTP 
analysis demonstrated that patients were willing to pay 
€68.14 to avoid a gain of 3 kg/6 months. In comparison with 
these, patients were willing to pay up to €54.80 to avoid one 
hypoglycemic event per month. Monthly WTP to reduce 
cardiovascular risk was €43.01, €42.74 to avoid nausea, 
and €24.28 to avoid a 1% increase in HbA
1c
. Regarding the 
mode of administration, patients were willing to pay up to 
€25.65 for one injection less per day. To gain flexibility 
when it came to injections (irrespective of meals instead of 
in relation to meals), patients were willing to pay €16.23 
per month. Oral antidiabetics were always preferred over 
injections in relation to meals or irrespective of meals. To 
reduce the frequency of blood glucose monitoring tests 
(one less per day), patients were willing to pay €10.19 per 
month (Table 4).
Potentially better clinical outcomes are preferred over 
poorer ones when all other things are kept constant. Neverthe-
less, in this study, there was a slight disordering of the WTP 
for the frequency of hypoglycemias and the weight attributes, 
where avoiding one hypoglycemia per month was valued 
more than avoiding one per week and losing 3 kg was valued 
more than losing 6 kg/6 months. However, these anomalies 
were not statistically significant (P0.05).
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Table 2 Patients’ and physicians’ sociodemographic and clinical characteristics
Patients’ sociodemographic  
characteristic
Spain Portugal Total
Mean SD Mean SD Mean SD
Age (years) 62.29 10.24 62.93 9.20 62.39 10.27
Time since diagnosis (years) 14.32 8.39 12.15 7.03 13.98 8.22
Weight (kg) 86.25 17.69 85.69 15.41 86.17 17.33
height (cm) 162.56 10.27 165.25 8.89 162.99 10.36
BMi (kg/m2) 32.70 7.01 31.45 5.69 32.50 6.82
n % n % n %
country 278 84 52 16 330 100
sex
Female 143 51.4 21 40.4 164 49.7
Male 133 47.8 31 59.6 164 49.7
level of education
Primary school 146 52.50 32 61.50 178 53.90
secondary school 74 26.60 12 23.10 86 26.10
University 41 14.70 5 9.60 46 13.90
Postgraduate 3 1.10 2 3.80 5 1.50
Other studies 12 4.30 1 1.90 13 3.90
Annual income
€12,000 129 46.40 31 59.60 160 48.50
€12,000–€20,000 74 26.60 13 25.00 87 26.40
€20,000–€30,000 48 17.30 3 5.80 51 15.50
€30,000–€50,000 11 4.00 4 7.70 15 4.50
€50,000 2 0.70 1 1.90 3 0.90
Weight change since diagnosis
Unchanged 46 16.50 15 28.80 61 18.50
has lost weight 75 27.00 15 28.80 90 27.30
has gained 0–2 kg 24 8.60 6 11.50 30 9.10
has gained 2–5 kg 39 14.00 6 11.50 45 13.60
has gained 5–10 kg 38 13.70 5 9.60 43 13.00
has gained 10 kg 54 19.40 5 9.60 59 17.90
T2DM complications
none 123 44.24 32 61.54 155 46.97
eye disease 69 24.82 6 11.54 75 22.73
Kidney problems 65 23.38 3 5.77 68 20.61
heart disease 79 28.42 6 11.54 85 25.76
Male impotence 19 6.83 3 5.77 22 6.67
nervous disease 17 6.12 1 1.92 18 5.45
Others 21 7.55 4 7.69 25 7.58
Frequency of hypoglycemia
One hypoglycemia per week 27 9.7 1 1.9 28 8.5
One hypoglycemia per month 62 22.3 6 11.5 68 20.6
One hypoglycemia per year 90 32.4 8 15.4 98 29.7
never had an hypoglycemia 99 35.6 37 71.2 136 41.2
last hbA1c level measured (%)
9 46 16.50 3 5.80 49 14.80
8–9 42 15.10 6 11.50 48 14.50
7–8 104 37.40 25 48.10 129 39.10
6 42 15.10 9 17.30 51 15.50
Frequency of blood glucose monitoring
Three times a day 46 16.50 3 5.80 49 14.80
Once a day 42 15.10 6 11.50 48 14.50
Three times a week 104 37.40 25 48.10 129 39.10
Once a month 42 15.10 9 17.30 51 15.50
none 35 12.60 9 17.30 44 13.30
nausea due to T2DM treatment
Yes 45 16.20 8 15.40 53 16.1
no 233 83.80 44 84.60 277 83.9
(Continued)
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Neither sex, being over 65 years old, having incomes above 
€12,000 a year, frequency of blood glucose control, frequency 
of hypoglycemias, HbA
1c
 value nor obesity were significant 
conditioning factors (P0.05) for patients’ preferences. Hav-
ing elapsed more than 10 years since the diagnosis and receiv-
ing injectable treatment were conditioning factors for patients’ 
preferences for the convenience attributes (Table S1).
Physicians’ results
Of the 221 professionals who participated in the study, the 
majority were Spaniards (81%). The sex distribution varied 
between countries, the proportion of women being 59.0% 
and 76.7% in Spain and Portugal, respectively. The mean 
age of physicians was 41.9 (SD: 10.5) years, being slightly 
younger in Portugal (39.3 [9.6] vs 42.5 [10.6]). Although 
in Portugal all the participants were primary-care doctors 
with a mean time since the beginning of practice of 13.3 
(9.7) years, in Spain, family physicians represented 58%, 
whereas the other 42% were endocrinologists, with a mean 
experience of treating patients with T2DM of 15.4 (11.3) 
years (Table 2).
Regarding antidiabetic attributes, data analyses showed 
that, with the exception of one hypoglycemic event per year 
and a bodyweight reduction of 3 kg/6 months, all attributes 
were significant predictors of choice (P0.05). Avoiding one 
hypoglycemic event per week was the most valuated attribute 
followed by avoiding gains in bodyweight of 3 kg/6 months 
and decreasing cardiovascular risk (Table 3).
For the attribute hypoglycemic events, physicians were 
willing to pay €287.18 to avoid one hypoglycemic event 
per week. In comparison with these, for the weight attribute, 
physicians were willing to pay €166.87 to avoid gaining 3 
kg. Monthly WTP to reduce cardiovascular risk was €154.30, 
€143.30 to avoid nausea, and €125.92 to avoid a 1% increase 
in HbA
1c
. Regarding the mode of administration, physicians 
were willing to pay up to €69.07 to reduce the number of 
injections to one less per day. To gain flexibility at the time 
of injections (irrespective of meals instead of in relation to 
meals), physicians were willing to pay €26.66. Oral antidi-
abetics were always preferred over injections in relation to 
meals, although the orals were considered comparable to 
injections irrespective of meals. Findings showed that physi-
cians were willing to pay €39.55 to reduce the frequency of 
blood glucose monitoring tests (one less per day) (Table 4).
Neither sex, country of origin, medical specialty nor 
having more than 10 years practicing the specialty were 
significant conditioning factors for physicians’ preferences 
(P0.05) (Table S1).
comparison between patients’ and 
physicians’ preferences
Considering the utility values obtained for the convenience 
and clinical attributes, the 16 scenarios were ordered from the 
most preferred to the last. These analysis demonstrated that 
both physicians and patients clearly preferred a similar treat-
ment: a medication that is administered by injection, once 
a day and irrespective of meals; that requires blood glucose 
monitoring three times per week; maintains HbA
1c
 between 
6% and 7%; reduces 6 kg/6 months; decreases cardiovascular 
risk; does not produce nausea; and is only associated to one 
Table 2 (Continued)
Patients’ sociodemographic  
characteristic
Spain Portugal Total
n % n % n %
Mode of treatment administration
injections +3/day in relation to meals 90 32.37 3 5.77 93 28.18
injections 2/day with meals 30 10.79 4 7.69 34 10.30
injections 1/day, not related to meals 86 30.94 5 9.62 91 27.58
OAD 1–2/day, with meals 137 49.28 41 78.85 178 53.94
Physicians’ sociodemographic 
characteristic
Mean SD Mean SD Mean SD
Age (years) 42.48 10.65 39.33 9.63 41.87 10.51
Time since the beginning of practice (years) 15.43 11.35 13.35 9.69 15.02 11.06
n % n % n %
country 178 80.5 43 19.5 221 100.00
sex
Female 105 59.00 33 76.70 138 62.40
Male 73 41.00 10 23.30 83 37.60
specialty
Primary care 104 58 43 100.00 147 66.50
endocrinologist 74 41.60 0 0 74 33.50
Abbreviations: BMi, body mass index; hbA1c, glycated hemoglobin; OAD, oral antidiabetics; T2DM, type 2 diabetes mellitus; sD, standard deviation.
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hypoglycemic event per year. Tables 5 and 6 described the 
preferred scenarios for both patients’ and physicians’.
Statistically significant differences (P0.05) were found 
in the preferences between physicians and patients regarding 
the attributes: mode of administration (injections once a day 
in relation to meals), blood glucose monitoring, hypoglyce-
mic events (one per month), hypoglycemic events (none), 
HbA
1c
, and additional payment per month (Table 3). Physi-
cians were willing to pay approximately three times more 
than patients for almost all attributes. Patients valued more 
than physicians reducing bodyweight by 3 kg in 6 months 
and the attributes of the mode of administration, specifi-
cally those regarding receiving oral antidiabetics instead of 
injected medication either in relation to or irrespective of 
meals (Figure 3).
Discussion
Results presented in this manuscript demonstrate that 
patients were willing to pay for improvements in their 
T2DM treatment, in order to gain additional benefits, just 
as stated by Bogelund et al23 and Jendle et al24 in their 
previous published studies. As that the evidence provided 
is unique for the studied population it can be considered 
paramount. Moreover, the information regarding patients’ 
and physicians’ preferences should be taken into account 
by health care decision makers given that participants were 
representative of both Spanish and Portuguese population. 
These outcomes can be considered as robust and may become 
important tools in the outcomes research area since they were 
product of a study that followed a rigorous methodology for 
its statistical analysis.
One of the main outcomes presented is that Spanish and 
Portuguese patients valued avoid gaining 3 kg/6 months the 
most followed by avoiding hypoglycemias. These results 
are in line with those presented in the previous studies. 
Mohamed et al27 performed an analysis of preferences for oral 
antidiabetics in Sweden and Germany and demonstrated that 
bodyweight gain was the most important attribute, followed 
by glucose control. Porzsolt et al10 showed that, to German 
physicians and patients, weight loss was as important as 
improvements in blood glucose control. Moreover, Jendle 
et al26 confirmed that patients placed great value on treatments 
that improved their glucose medication while avoiding gains 
in bodyweight and involved the administration of fewer injec-
tions. These consistent findings might be explained by the 
fact that patients are aware of the consequences of obesity 
on glucose control and other diabetes comorbidities such as 
cardiovascular risk.
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Table 5 Physicians’ and patients’ preferences for the convenience attributes
Patients’ preferred  
treatment
Mode of administration Blood glucose  
monitoring
Additional  
payment/month (€)
Physicians’ preferred 
treatment
1 injection 1/day irrespective of meals Three times per week 0 1
2 OAD up to 3/day with meals no need for testing 20 2
3 injection 1/day in relation to meal no need for testing 0 3
4 OAD up to 3/day with meals Three times a day 0 9
5 injection 1/day irrespective of meals Once a day 20 5
6 OAD up to 3/day with meals Once a day 50 6
7 injection 1/day irrespective of meals no need for testing 50 4
8 injection 2/day in relation to meals Once a day 0 11
9 injection 2/day in relation to meals Three times per week 20 10
10 injection 1/day in relation to meals Three times a day 20 12
11 injection 1/day in relation to meals Three times per week 50 7
12 OAD up to 3/day with meals Three times per week 100 8
13 injection 2/day in relation to meals Three times a day 50 16
14 injection 1/day in relation to meals Once a day 100 13
15 injection 1/day irrespective of meals Three times a day 100 15
16 injection 2/day in relation to meals no need for testing 100 14
Abbreviation: OAD, oral antidiabetics.
Table 6 Physicians’ and patients’ preferences for the clinical attributes
Patients’ preferred 
treatment
No of hypoglycemic 
events
HbA1c Weight  
change/ 
6 months
Nauseas/ 
3 months
CVR Additional  
payment  
per month (€)
Physicians’ 
preferred  
treatment
1 1/year 6%–7% lose 6 kg none Decreases 0 1
2 1/week 6% lose 3 kg none Decreases 20 4
3 none 7%–8% lose 6 kg none The same 20 5
4 1/month 6% lose 6 kg Mild nausea Decreases 50 3
5 none 8% The same none Decreases 50 7
6 none 6%–7% lose 3 kg Mild nausea Decreases 100 6
7 1/month 8% lose 3 kg none The same 0 14
8 1/week 7%–8% The same Mild nausea Decreases 0 13
9 1/year 6% The same none The same 100 2
10 none 6% gain 3 kg Mild nausea The same 0 8
11 1/month 6%–7% The same Mild nausea The same 20 10
12 1/year 7%–8% lose 3 kg Mild nausea The same 50 9
13 1/year 8% gain 3 kg Mild nausea Decreases 20 11
14 1/week 6%–7% gain 3 kg none The same 50 15
15 1/month 7%–8% gain 3 kg none Decreases 100 12
16 1/week 8% lose 6 kg Mild nausea The same 100 16
Abbreviations: cVr, cardiovascular risk; hbA1c, glycated hemoglobin; no, number.
Regarding the mode of administration, it is clear that 
patients preferred oral antidiabetics to injected medications. 
Hauber et al50 showed that patients with T2DM were willing 
to pay for improvements in dosing, efficacy, and safety, being 
this WTP dependent on the therapy currently being received. 
However, in the current study, although patients were will-
ing to pay up to €30.16 to receive oral antidiabetics instead 
of injections in relation to meals, the preferred hypothetical 
treatment was the one administered once a day as an injec-
tion irrespective of meals associated with blood glucose 
monitoring three times per day and without additional cost. 
An explanation for these results might be that patients value 
oral antidiabetics almost the same as injections irrespective 
of meals and because flexible dosing might have a positive 
impact on HRQoL, which can potentially enhance adher-
ence and could contribute to improve long-term outcomes, 
as described by Evans et al.51
In this study, there was a slight disordering on the WTP 
for the frequency of hypoglycemias and the weight attributes, 
although these differences were not statistically significant. 
Poulos et al,11 Mohamed et al,27 and Hauber et al50 among others, 
have described similar inconsistencies in their publications, 
indicating that T2DM patients frequently fail to make a distinc-
tion among some levels of a given antidiabetic attribute.
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Another important finding is that physicians’ in Spain and 
Portugal rated avoiding one hypoglycemic event per week, 
avoiding gaining 3 kg/6 months, and decreasing cardiovas-
cular risk as being more valuable T2DM treatment attributes 
than avoiding a 1% increase in HbA
1c
. Physicians’ prefer-
ences for T2DM treatment attributes are rarely discussed 
in the literature, and far less frequently the WTP for such a 
characteristic. Only two publications on these subjects have 
been identified and their results concurred with the ones 
presented in the current study. Porzsolt et al10 examined 
the German physicians’ and patients’ relative preferences 
for glucose control, side effects, convenience, and weight 
change attributes. Their results demonstrated that physicians 
considered bodyweight change to be at least as important as 
blood glucose monitoring. Moreover, Poulos et al11 studied 
physicians’ preferences for extra glycemic effects of T2DM 
treatments in United States and United Kingdom. Their 
results showed that glucose control (HbA
1c
) was the most 
important attribute followed by reducing cardiovascular risk 
and change in bodyweight.
The outcomes previously described are not surprising 
at all, since educational programs for health care providers 
have created an awareness of the risk of hypoglycemia, and 
the risk, during tight glycemic management of diabetes, of 
its association with an increase in cardiovascular events and 
its relation to other detrimental effects such as lessening of 
HRQoL, treatment satisfaction and, ultimately, adherence to 
treatment.52 Furthermore, given that cardiovascular disease is 
Figure 3 comparison of physicians’ and patients’ monthly WTP for diabetes treatment attributes.
Abbreviations: hbA1c, glycated hemoglobin; WTP, willingness to pay.
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the major cause of death in patients with T2DM and obesity 
is a risk factor for both conditions, it is only logical that those 
attributes are highly valued by health care providers.53 Weight 
loss is considered as a key factor in the management of T2DM 
and the reduction of mortality associated with the disease.54 
As a result, health care providers consider weight gain as 
extremely detrimental to diabetic patients’ health, thereby 
suggesting that avoiding even a relatively small weight gain 
is more important than reducing weight.55
Both patients and physicians in Spain and Portugal were 
willing to pay for the health benefits associated with better 
diabetes treatment, avoiding hypoglycemia and weight gain 
being paramount. These results comply with the Prospect 
Theory of Kahneman and Tversky, which proposes that in 
general people’s aversion for losses is greater than attrac-
tion for benefits.56 Mühlbacher and Juhnke12 stated that for 
chronic conditions such as T2DM and especially in studies 
that utilized DCE there is usually a higher agreement level 
between patients’ and physicians’ responses. However, these 
similarities depend on the type of attribute being assessed. 
Attributes focused on outcomes (HbA
1c
 and hypoglycemia) 
are usually more highly valued by physicians, while patients 
add less value to attributes that can negatively affect their 
HRQoL. Concurring with the previous statement, in this 
study differences between physicians’ and patients’ prefer-
ences were only statistically significant for HbA
1c
, frequency 
of hypoglycemia, injections in relation to meals, frequency 
of blood glucose monitoring, and payment, these attributes 
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being less valued by patients than by physicians in all cases. 
Although in their study Porzsolt et al10 did not statistically 
compare the results of patients’ and physicians’ preferences, 
their findings were in line with the ones presented in this 
study. Physicians preferred the attributes related to effi-
ciency while patients preferred the convenience and HRQoL 
improving attributes.
Regarding the payment attribute, physicians were will-
ing to pay up to three times more than patients for almost all 
attributes with the exception of receiving oral antidiabetics 
instead of injected medications. These differences have also 
been described in other publications12,57 and can be explained 
based on the distinct perspectives of patients and physicians. 
Patients were asked to choose which treatment they preferred 
for themselves, while physicians were asked which treat-
ment they would prefer to prescribe. Moreover, health care 
providers make decisions drawing on scientific information 
and are aware of the real value of each characteristic of a 
therapeutic measure, which might help increase the WTP 
for such attributes.58 On the other hand, given the current 
economic situation in both Spain and Portugal, together with 
the high level of reimbursement of antidiabetic treatments, 
it could lead to a lower patients’ WTP.
study limitations
The use of DCE and conditional logit models is the recom-
mended approach for measuring participants’ preferences 
and determining WTP.20,30 However, DCE is a technique for 
measuring stated preferences and even though it resembles 
the real consumer’s choice, there is always a gap between 
stated and revealed preferences.15,20 For this reason, cau-
tion should be paid given the probability that respondents 
presented different preferences in this survey from the ones 
they would state in a real-life situation.
In addition, there is some uncertainty associated with 
the interpretation of the exercise by patients and how it may 
affect the results. Although the selection of the choice levels 
was performed according to the ISPOR recommendations, 
some of the attributes might not match the currently avail-
able treatments and in some instances the presented scenario 
was less favorable than the treatment patients were already 
taking. Nonetheless, all participants received a clear expla-
nation before answering the questionnaire stating that all 
presented treatments were hypothetical and in no case were 
to be compared against their current treatment.
Another limitation is that some of the WTP 95% CI 
can be considered wide which could suggest heterogeneity 
in the responses. This finding could be due to the use of 
the conditional logit model. This model assumes that the 
measured utility is equal across all respondents and choice 
questions, and therefore does not recognize unobserved 
systematic relationships in preferences among respondents 
(preference heterogeneity).59,60 Nevertheless, the conditional 
logit model has the ability to provide efficient estimators.40 
Finally, results obtained from this study should be interpreted 
in the context where they were obtained. Future research 
regarding preferences of patients in the subpopulations with 
conditioning characteristic is warranted.
Conclusion
Both patients and physicians in Spain and Portugal are willing 
to pay for the health benefits associated with improved 
diabetes treatment, the most important being to avoid both 
hypoglycemia and gaining bodyweight. Decreased cardio-
vascular risk and weight reduction became the third most 
valued attributes of antidiabetics for physicians and patients, 
respectively.
Physicians and patients had different preferences 
regarding the attributes mode of administration (injections 
once a day in relation to meals), blood glucose monitoring, 
hypoglycemic events (one per month), hypoglycemic events 
(none), HbA
1c
, and additional payment per month. Patients 
valued more than physicians reducing bodyweight by 3 kg 
in 6 months and the attributes of the mode of administra-
tion, specifically those regarding receiving oral antidiabet-
ics instead of injected medication either in relation to or 
irrespective of meals.
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Table S1 Patients’ and physicians’ conditioning factors P-values results obtained by the multinomial model
Convenience attributes (P-value) Clinical attributes (P-value)
Patients’ characteristics
sex 0.1706 0.2626
Being 65 years 0.2726 0.9263
having incomes above €12,000 a year 0.1898 0.6045
Blood glucose control 1/day 0.8984 0.9375
Blood glucose control 3/day 0.4034 0.2662
Blood glucose control 1/month 0.1763 0.8459
no need for glucose control 0.5483 0.1529
hypoglycemia 1/month 0.3977 0.6653
hypoglycemia 1/month 0.8749 0.5689
never had hypoglycemia 0.3856 0.8026
hbA1c 8%–9% 0.5366 0.8342
hbA1c 7%–8% 0.9104 0.7592
hbA1c 6% 0.4873 0.7888
hbA1c unknown 0.5150 0.8570
Obesity 0.5173 0.1160
More than 10 years since the diagnosis 0.0281 0.7682
receiving injectable treatment 0.0394 0.7395
Physicians’ characteristics
sex 0.5614 0.0847
Medical specialty 0.3180 0.3051
Time since beginning of practice longer than 10 years 0.0717 0.7243
country 0.4044 0.1023
Note: Bold values indicate significance value P0.05.
Abbreviation: hbA1c, glycated hemoglobin.
